Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 22 Show results per page	View Search Criteria \| Help With Results


1.		Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				1 to 14				Other				2005-000658-56 20040177, 2004-41-4276, NCT00192673

Last Modified: 10/17/2008 First Published: 12/23/2003


2.		Phase III Randomized Study of Dexamethasone Versus Prednisone During Induction and High-Dose Methotrexate With Leucovorin Rescue Versus Escalating-Dose Methotrexate Without Leucovorin Rescue During Interim Maintenance I in Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				1 to 30				NCI				COG-AALL0232 NCT00075725, AALL0232

Last Modified: 10/17/2008 First Published: 1/24/2005


3.		Phase III Randomized Study of Different Combination Chemotherapy Regimens in Pediatric Patients With Newly Diagnosed Standard-Risk B-Precursor Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				1 to 9				NCI				COG-AALL0331 AALL0331, NCT00103285

Last Modified: 6/17/2008 First Published: 11/13/2006


4.		Phase III Randomized Study of Pegasparaginase Verus E. coli Asparaginase With Combination Chemotherapy in Children With Newly Diagnosed Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				1 to 17				NCI				DFCI-05001 NCT00400946

Last Modified: 10/17/2008 First Published: 11/22/2006


5.		Phase III Randomized Study of Augmented Berlin-Frankfurt-Münster-86 Multiagent Chemotherapy, Intensified Methotrexate, and Nelarabine in Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				1 to 30				NCI				COG-AALL0434 AALL0434, NCT00408005


6.		A Study of Actonel for the Prevention of Bone Loss

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Active				18 and over				Other				ID03-0124 NCT00452439

Last Modified: 10/17/2008 First Published: 11/6/2007


7.		Phase III Partially Randomized Study of Risk-Directed Therapy Comprising a Modified P9407 Chemotherapy Backbone With or Without Lestaurtinib in Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				Under 1 at diagnosis				NCI				COG-AALL0631 AALL0631, NCT00557193


8.		Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and under				NCI, Other				TOTXVI NCT00549848


9.		Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Over 1 and under 21				Other				T2005-003 NCT00440726

Last Modified: 10/17/2008 First Published: 11/22/2004


10.		Phase II Pilot Study of Epratuzumab Alone and in Combination With Re-Induction Combination Chemotherapy in Pediatric Patients With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (Part A closed to accrual as of 10/30/06)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				2 to 31				NCI				COG-ADVL04P2 ADVL04P2, NCT00098839

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute